GSK/Corixa Bexxar cmte. review?
Executive Summary
GlaxoSmithKline/Corixa's Bexxar (tositumomab) is slated for review for treatment of low-grade or transformed low-grade non-Hodgkin's lymphoma by FDA's Oncologic Drugs Advisory Committee at the tentatively scheduled Dec. 17-18 meeting. Corixa requested committee review of the drug in its appeal of a March 12 "complete response" letter (1"The Pink Sheet" May 20, In Brief). The company has said it expected a review of Bexxar before year-end (2"The Pink Sheet" Aug. 12, In Brief)...
You may also be interested in...
AstraZeneca Casodex FDA Cmte. To Focus On Efficacy Differences In Trials
AstraZeneca expects FDA's Oncologic Drugs Advisory Committee's Casodex review to focus on the apparent lower efficacy of the prostate cancer drug in U.S. trials compared to those outside the U.S
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.